Medicap Healthcare Limited

Medicap Healthcare Limited (New IPO): GMP, Profit, Price & expert review

by

Medicap Healthcare Limited, a Vadodara-based is a young and dynamic company dedicated towards manufacturing of closures for pharmaceutical industry, particularly Euro Head caps.

Medicap is a B2B manufacturer and commands a 40% domestic market share in Euro Head caps and approximately 1.4% globally. The company serves major pharmaceutical clients across 14 countries, maintaining long-term relationships where repeat customers contribute over 90% of total revenue.

Medicap Healthcare Limited has filed DRHP with SEBI for a proposed IPO of ₹ 240 Cr consisting entirely as Fresh Issue of ₹ 240 Cr & no Offer for Sale (OFS).

Subscription date to apply for the IPO is yet to be announced. Price band for the IPO is also pending to be declared.

Check DRHP
Check IPO Allotment
Visit Official Website
Issue Size:₹ 240 Cr
Fresh Issue:₹ 240 Cr
Offer for Sale:₹ 00 Cr
Price Range:TBA
Lot Size:TBA
GMPPending

Medicap Healthcare Limited important data points

Revenue, PAT, EBITDA

YearFiscal 2025
Networth₹ 110.84 Cr
Revenue:₹ 108.30 Cr
EBITDA₹ 37.15 Cr
PAT₹ 26.61 Cr
EBITDA Margin:~24.58%
PAT Margin~24.58%
Face Value:₹ 10 Per Equity Shares

IPO important dates

Open Date:TBA
Close Date:TBA
Anchor Investor BiddingTBA
Allotment Date:TBA
Refunds & Demat CreditTBA
Tentative Listing Date:TBA

Use of Proceeds

PurposeAmount
Borrowing repayment~ ₹ 32.90 Cr
Purchase of plant & machinery~ ₹ 74.37 Cr
Investment in subsidiary~ ₹ 52.80 Cr
General Corporate PurposeBalance

Medicap Healthcare Limited Financial Data

202320242025
Revenue (₹ Cr)₹ 71.6₹ 102.1₹ 108.3
PAT (₹ Cr)₹ 14.8₹ 23.9₹ 26.6
Asset (₹ Cr)₹ 98.3₹ 105.9₹ 216.2
Net Worth (₹ Cr)₹ 60.3₹ 84.2₹ 110.8

Medicap Healthcare Ltd IPO Grey Market Premium

DateIPO PriceIPO GMPProfit per lot
11-Mar₹ –₹ –₹ –
10-Mar₹ –₹ –₹ –
09-Mar₹ –₹ –₹ –
08-Mar₹ –₹ –₹ –
07-Mar₹ –₹ –₹ –
Medicap Healthcare Limited

Medicap Healthcare Limited IPO Pros & Cons

Strengths:

  • Market Dominance: Commands a leading 40% domestic market share in specialized Euro Head cap packaging components.
  • High Profitability: Achieved a strong 34% CAGR in Profit After Tax between FY23 and FY25.
  • Customer Loyalty: Exceptional client retention with over 90% of revenue coming from consistent repeat customers.
  • Strategic Expansion: IPO funds will nearly double production capacity and integrate vertical IV fluid manufacturing.
  • Global Footprint: Successfully exports high-precision pharmaceutical packaging to major clients across 14 different international countries.

Risks:

  • Product Concentration: Heavy reliance on a narrow product range makes revenue vulnerable to specific segment shifts.
  • Client Concentration: Significant revenue depends on a limited number of large pharmaceutical companies’ procurement decisions.
  • Regulatory Sensitivity: Must constantly meet rigorous global healthcare standards; any compliance failure could halt operations.
  • Capital Intensity: Business requires high ongoing investment in advanced machinery, which may pressure future liquidity.
  • Raw Material Volatility: Profit margins are sensitive to price fluctuations in plastic resins and medical-grade polymers.

Medicap Healthcare Limited Promoters – Pre offer equity (Approx)

Promoters%Shares
Kamalkumar Aggarwal~90%
Rajveer Kamal Aggarwal~5%
Minal Aggarwal~1%
––
––

Medicap Healthcare Limited Lot Size details

Application TypeLot SizeNo. of LotNo. of SharesInvestment Amount
Retail (Min)–1–₹ –
Retail (Max)–13–₹ –
HNI (Min)–14–₹ –
HNI (Max)–66–₹ –
Big HNI (Min)–67–₹ –

Lead Managers / Registrars of Medicap Healthcare Limited 

Lead / Book Running Lead ManagersAryaman Financial Services Limited
Registrar (RTA)KFin Technologies Limited

Medicap Healthcare Limited FAQ

For more amazing blogs click here (IPO Corner).

facebookShare on Facebook
TwitterPost on X
FollowFollow us
PinterestSave

Leave a comment

RSS
Follow by Email
Facebook
X (Twitter)
Pinterest
Instagram
Telegram
WhatsApp